[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pregnancy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pregnancy":25},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,271,0,25,[9,46,75,102,128,152,182,210,233,255,277,312,340,364,392,415,444,473,495,521,562,589,612,634,658],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100489688","a-repository-to-study-host-microbiome-interactions-in-health-and-disease-100489688",false,"NCT05656378","A Repository to Study Host-Microbiome Interactions in Health and Disease","* INCLUSION CRITERIA:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n* Aged \\>0 years. Only participants \\>3 years old will be seen at the NIH CC.\n* Willing to allow biological samples and data to be stored for future research.\n* Willing to provide at least one of the requested biospecimens.\n\nEXCLUSION CRITERIA:\n\n* An individual who has any condition that, in the judgment of the investigator, may put them at undue risk or make them unsuitable for participation in the study will be excluded.\n* For additional gastrointestinal and skin biopsies only, individuals on blood thinners unless they have already been stopped for the procedure, and children aged younger than 3 years.\n* For additional gastrointestinal biopsies only, individuals who have a history of gastrointestinal perforation with endoscopic biopsies will be excluded from the collection of additional gastrointestinal biopsies for the repository.\n* For additional gastrointestinal biopsies only, healthy children (\\\u003C18 years old).\n* For skin biopsies only, individuals who have a history of keloid formation.\n* For vaginal swabs and vaginal fluid only, individuals who have not started menses.\n* For breast milk only, non-lactating individuals.",true,"ALL",{"count":19,"type":20},600,"ESTIMATED","OBSERVATIONAL","Background:\n\nThe microbiome is the bacteria and other microorganisms that live inside and on the body. The microbiome is important for our health. Researchers study how the microbiome help people stay healthy. They study how the microbiome affects the body when people get sick. To do this research, they need samples of the microbiome living on the bodies of many people. The purpose of this natural history study is to collect microbiome samples in a repository. These samples will be used for future research.\n\nObjective:\n\nTo collect microbiome samples from the body that can be used for future research.\n\nEligibility:\n\nPeople of any age. Only those older than 3 years will be seen at the NIH clinic.\n\nDesign:\n\nParticipants will fill out a questionnaire. Topics will include their medical history and foods they eat.\n\nParticipants will be asked to give 1 or more of the following:\n\nStool, urine, saliva, vaginal fluid, and breastmilk. These samples can be collected at home and sent to the researchers.\n\nCells from participants cheek, nose, mouth, skin, rectum, and\u002For vagina. The cells may be collected by rubbing the area with a sterile cotton swab. These procedures can also be done at home.\n\nBlood. Blood may be drawn using a needle inserted into a vein in the arm. For young children, blood may be collected by a prick on the heel or finger.\n\nIntestinal tissue samples. These may be collected from participants who are having an endoscopy or colonoscopy for other reasons.\n\nSkin tissue samples. These may be collected from participants who are having biopsies for other reasons.",[24,25,26,27],"Healthy Controls","Pregnancy","Pediatric Illnesses","Inflammatory Diseases",[29,30,31,25,32],"Microbiome","Host Response","Children","Natural History","RECRUITING","2026-08-20",{"date":36,"type":37},"2026-08-21","ACTUAL",{"date":39,"type":37},"2023-03-09",{"date":41,"type":20},"2032-01-01",{"name":43,"class":44},"National Institute of Allergy and Infectious Diseases (NIAID)","NIH",1,{"id":47,"slug":48,"hasResults":12,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":12,"sex":53,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":4},"100601272","provider-and-patient-rct-promote-100601272","NCT07108335","Provider and Patient RCT PROMOTE","Provider Randomized Trial of the PROvider ReMote ObsTetric-Related Employment Education (PROMOTE)","Inclusion Criteria - Participants:\n\n* Pregnant patients who are 24 - 32 weeks gestation\n* Employed or unemployed and seeking paid employment\n\nInclusion Criteria - Providers:\n\n* Clinical team member (doctor, nurse, advanced practice provider, any medical assistant or administrative staff)\n\nExclusion Criteria - Participants:\n\n* Non- English language fluency\n* Unemployed with no desire to seek paid employment\n\nExclusion Criteria - Providers:\n\n* Not a clinical team member","FEMALE","18 Years","65 Years",{"count":57,"type":20},404,"INTERVENTIONAL",[60],"NA","Research Aim 1: Determine the effectiveness of PROMOTE vs. usual care to increase patients' receipt of counseling about workplace accommodations and pregnancy. Investigators will recruit and randomize Obstetric providers to the PROMOTE intervention or usual care. The investigators will compare the frequency of EHR documented work- related counseling and adherence to employer documentation recommendations between the two study arms.\n\nHypothesis: Patients receiving care by a provider randomized to PROMOTE will have higher rates of documented counseling about work and pregnancy.\n\nResearch Aim 2: Determine the effectiveness of PROMOTE vs. usual care to reduce undesired wage or advancement reduction, increase accommodation requests granted, and improve maternal-infant health. The investigators will recruit a racially and socioeconomically diverse cohort of 304 pregnant patients and compare responses to surveys and qualitative interviews about work experiences and EHR-documented maternal-infant health outcomes among patients receiving care by providers randomized to PROMOTE vs. usual care.\n\nHypothesis: Compared to patients receiving care by providers randomized to usual care, participants receiving care by providers randomized to PROMOTE will have less undesired loss of wages and advancement, increased accommodation request granted, and improved maternal-infant health during pregnancy.",[63,25,64],"Maternal Health","Employment","NOT_YET_RECRUITING","2026-08-19",{"date":34,"type":37},{"date":69,"type":20},"2026-10-01",{"date":71,"type":20},"2029-08",{"name":73,"class":74},"Duke University","OTHER",{"id":76,"slug":77,"hasResults":12,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":12,"sex":53,"minAge":54,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":58,"phases":85,"briefSummary":86,"conditions":87,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":45},"100621955","cheer-oral-health-in-pregnancy-study-100621955","NCT07377344","CHEER Oral Health in Pregnancy Study","Closing Health Equity Through Empowering Oral Health for Maternal Wellness","CHEER","Inclusion Criteria:\n\n1. Pregnant individuals aged 18 years or older with indications of periodontal diseases (gingivitis or mild periodontitis, moderate to severe periodontitis)\n2. Less than 20 weeks pregnancy at time of enrollment\n3. Has dental insurance (Medi-Cal or private coverage)\n4. Willing and able to provide informed consent\n5. Planning to receive ongoing prenatal care at study-affiliated clinics\n6. Access to a mobile phone for receiving text messages\n\nExclusion Criteria:\n\n1. Presence of systemic diseases or medical conditions that require antibiotic prophylaxis for dental procedures\n2. Current immunosuppressive therapy\u002Fuse of anti-inflammatory medications\n3. Receipt of active periodontal treatment within the past 6 months\n4. Complete edentulism (no natural teeth)\n5. Unable to read and write English\n6. Less than 9th grade education\n7. Enrollment in another oral interventional study",{"count":84,"type":20},160,[60],"Many pregnant people don't get the dental care they need, even though it's safe and important. The CHEER Study offers free dental check-ups, cleanings, and supplies to help participants take care of their teeth and gums during pregnancy. The purpose of this research study is to compare two types of noninvasive oral health interventions to evaluate their effectiveness. We want to learn if one method is more effective in supporting oral health and improving pregnancy outcomes. There are two aims of this study:\n\nAim 1: To evaluate whether a structured oral health intervention reduces periodontal inflammation during pregnancy and postpartum in pregnant people with indicators of periodontal disease.\n\nAim 2: To assess whether a structured oral health intervention is associated with changes in oral health behaviors or birth outcomes in pregnant people with periodontal disease.",[88,89,25,90,91,92,93],"Gingivitis","Dental Health","Pregnancy Outcomes","Randomized Controlled Trial","Periodontal Disease","Gum Disease","2026-08-18",{"date":34,"type":37},{"date":97,"type":20},"2026-09-30",{"date":99,"type":20},"2028-12-31",{"name":101,"class":74},"University of California, San Francisco",{"id":103,"slug":104,"hasResults":12,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":12,"sex":53,"minAge":4,"maxAge":4,"enrollmentInfo":109,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":111,"conditions":112,"keywords":116,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":119,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":127},"100524784","pregnancy-surveillance-program-of-patients-exposed-to-epidiolexepidyolex-during-pregnancy-100524784","NCT06113237","Pregnancy Surveillance Program of Patients Exposed to Epidiolex\u002FEpidyolex During Pregnancy","Observational Pregnancy Surveillance Program of Patients Exposed to Epidiolex\u002FEpidyolex During Pregnancy to Assess the Risk of Pregnancy and Maternal Complications and Other Events of Interest on the Developing Fetus, Neonate, and Infant","Inclusion Criteria:\n\n1. Patients with exposure to at least 1 dose of Epidiolex\u002FEpidyolex during the 13 days prior to their LMP or at any time during pregnancy.\n2. Verbal or written informed consent to participate\n\nExclusion criteria:\n\n1\\) Patients exposed to a non-regulatory approved product containing Cannabidiol (CBD) during pregnancy who do not also have exposure to Epidiolex during the 13 days prior to their LMP or during the pregnancy.",{"count":110,"type":20},50,"The purpose of this study is to evaluate pregnancy-related health outcomes in participants who are exposed to Epidiolex\u002FEpidyolex during pregnancy and their infant up to 12 months of life.",[113,114,115,25],"Maternal Complications","Pregnancy Complication","Birth Outcomes, Adverse",[117,118],"Epidiolex","Epidyolex",{"date":34,"type":37},{"date":121,"type":37},"2025-08-05",{"date":123,"type":20},"2033-08-31",{"name":125,"class":126},"Jazz Pharmaceuticals","INDUSTRY",2,{"id":129,"slug":130,"hasResults":12,"nctId":131,"briefTitle":132,"officialTitle":132,"acronym":4,"eligibilityCriteria":133,"healthyVolunteers":16,"sex":53,"minAge":54,"maxAge":134,"enrollmentInfo":135,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":137,"conditions":138,"keywords":140,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":45},"100652666","are-there-any-clinical-benefits-to-screening-for-late--onset-gestational-diabetes-mellitus-100652666","NCT07776314","Are There Any Clinical Benefits to Screening for Late -Onset Gestational Diabetes Mellitus?\"","Inclusion Criteria:\n\n* Gestational Age: Confirmed singleton pregnancy between 32+0 and 34+6 weeks of gestation based on the last menstrual period (LMP) and\u002For first-trimester crown-rump length (CRL) ultrasound measurement.\n\nFollow-up: Intention and willingness to deliver at the study hospital and complete all planned follow-up visits until the end of the postpartum period.\n\nInformed Consent: Voluntary agreement to participate in the study evidenced by signed written informed consent.\n\nExclusion Criteria:\n\n* Multifetal pregnancies (e.g., twins, triplets) Fetal Anomalies Pre-gestational Chronic Diseases Protocol Non-compliance \u002F Loss to Follow-up Preterm Birth \u002F Preterm Labor","45 Years",{"count":136,"type":20},128,"This study aims to screen women who have a negative Gestational diabetes mellitus (GDM) result in routine screening tests or who have never had it with the Fasting Blood Glucose Test (FBG) at 32-34 weeks of gestation to diagnose late-onset GDM with routine FBG ≥5.1 mmol\u002FL (92mg\u002Fdl) in fasting blood, and to investigate its connection with perinatal and maternal outcomes, hoping to inform about late-stage GDM.",[139,25,90],"Pregnancy in Diabetes",[141,142,143],"late-onset gestationel diabetes mellitus","benefits to screening for late -onset Gestational Diabetes Mellitus","Gestational Diabetes Mellitus","2026-08-17",{"date":34,"type":37},{"date":147,"type":37},"2025-03-13",{"date":149,"type":20},"2026-11-10",{"name":151,"class":74},"Izmir Ataturk Training and Research Hospital",{"id":153,"slug":154,"hasResults":12,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":158,"eligibilityCriteria":159,"healthyVolunteers":12,"sex":53,"minAge":54,"maxAge":4,"enrollmentInfo":160,"targetDuration":4,"studyType":58,"phases":162,"briefSummary":164,"conditions":165,"keywords":167,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":175,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":45},"100652617","phase-2-substance-use-in-pregnancy---optimizing-retention-in-treatment-by-maximizing-opportunities-for-management-100652617","NCT07776457","Substance Use in Pregnancy - Optimizing Retention in Treatment by Maximizing Opportunities for Management","Substance Use in Pregnancy- Optimizing Retention in Treatment by Maximizing Opportunities for Management","SUPPORT MOM","Inclusion Criteria:\n\n* Confirmed viable intrauterine pregnancy at any gestational age; OR postpartum with at least six months remaining until 365 days after deliver\n* Diagnosis of SUD as defined by DSM-5 and\u002For as documented in the clinical record\n* 18 years of age or older\n* Two or more positive domains in first screening for social drivers of health\n* Receiving ongoing care at participating study site\n\nExclusion Criteria:\n\n* Declining follow-up care at participating study site\n* Participated in R61 pilot study for CM\n* Requiring immediate hospitalization for unstable medical or psychiatric conditions making patient clinically unsuitable for research participation at the time of enrollment approach\n* Unable to participate in English",{"count":161,"type":20},245,[163],"PHASE2","Overdose is a national top-three leading cause of pregnancy-associated death, and maternal substance use disorder (SUD) accounts for an estimated $1.5 billion in healthcare spending each year. Treatment with medication and behavioral therapy lowers morbidity and overdose risk. However, studies have shown 55% to 80% of patients stop treatment within one year postpartum. Additionally, as a result of systemic inequities, historically marginalized patients are at greatest risk of overdose or death. We are conducting a study at WashU Medicine and University of Maryland, Baltimore clinics that offer prenatal care, addiction treatment, and extended postpartum support for patients facing the challenges of a SUD. Study participants will complete a structured screening and management of their social needs, and then will be randomly assigned to continue their usual care or to participate in a contingency management program, which provides incentives to continue treatment.",[25,166],"Substance Use Disorder (SUD)",[168,169,170,171,172,173,174],"randomized","pregnancy","prenatal","substance use disorder","contingency management","postpartum","intervention",{"date":34,"type":37},{"date":177,"type":20},"2027-01",{"date":179,"type":20},"2030-02",{"name":181,"class":74},"Washington University School of Medicine",{"id":183,"slug":184,"hasResults":12,"nctId":185,"briefTitle":186,"officialTitle":186,"acronym":4,"eligibilityCriteria":187,"healthyVolunteers":16,"sex":53,"minAge":54,"maxAge":4,"enrollmentInfo":188,"targetDuration":4,"studyType":58,"phases":190,"briefSummary":191,"conditions":192,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":202,"startDateStruct":204,"completionDateStruct":206,"leadSponsor":208,"locationsCount":45},"100497921","understanding-the-role-of-doulas-in-supporting-people-with-pmads-100497921","NCT05763537","Understanding the Role of Doulas in Supporting People With PMADs","Inclusion Criteria:\n\n* Participants must be over the age of 18\n* Currently pregnant and between 13 and 26 gestational weeks at the time of enrollment\n* Live in a HRSA-designated rural area of Montana\n\nExclusion Criteria:\n\n* They are under the age of 18\n* Not currently pregnant\n* Not between 13-26 gestational weeks at the time of enrollment\n* If they do not live in a HRSA-designated rural are of Montana.",{"count":189,"type":20},75,[60],"Detailed Description The doula-led intervention developed during the first phase of this project will be pilot tested for feasibility. Following the recruitment procedures described in the recruitment and retention plan, approximately 75 participants will be enrolled into the study. Twenty-five of the participants will receive regular doula care and 25 of the participants will receive care from a doula trained in the PMAD doula training throughout their pregnancy, childbirth, and postpartum time period, following the intervention procedures developed in Aim 2 of this study. Twenty-five women will not receive care from a doula and will receive perinatal care as usual. Women in all groups will take surveys via REDCap during their enrollment in the intervention, at 1 month postpartum, 3 months, and 6 months postpartum (at the conclusion of the intervention). All participants who receive the PMAD doula intervention will complete checklists after each session with their doula, to assess fidelity to the intervention. Participant communication with their doula via patient notebook will also be assessed for fidelity to the intervention.",[63,25,193,194,195,196,197,198,199,200],"Delivery, Obstetric","Self Efficacy","Social Support","Mental Health","Substance-Related Disorders","Postpartum Depression","Depression","Mental Health Services","2026-08-12",{"date":203,"type":37},"2026-08-14",{"date":205,"type":37},"2024-11-26",{"date":207,"type":20},"2026-12-31",{"name":209,"class":74},"University of Montana",{"id":211,"slug":212,"hasResults":12,"nctId":213,"briefTitle":214,"officialTitle":215,"acronym":216,"eligibilityCriteria":217,"healthyVolunteers":16,"sex":53,"minAge":54,"maxAge":218,"enrollmentInfo":219,"targetDuration":4,"studyType":58,"phases":221,"briefSummary":222,"conditions":223,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":224,"lastUpdatePostDateStruct":225,"startDateStruct":227,"completionDateStruct":229,"leadSponsor":231,"locationsCount":127},"100651555","epigenetic-and-cortisol-level-reflections-of-maternal-stress-during-pregnancy-100651555","NCT07764380","Epigenetic and Cortisol Level Reflections of Maternal Stress During Pregnancy","Epigenetic and Cortisol Level Reflections of Maternal Stress During Pregnancy: A Randomized Controlled Trial on the Effectiveness of Educational Programs","Maternal Stres","Inclusion Criteria:\n\n* Pregnant women aged 18 and older\n* Pregnant women in any trimester of pregnancy\n* Pregnant women who can read and understand Turkish\n* Pregnant women who voluntarily agree to participate in the study\n* Having a singleton pregnancy\n* Pregnant women without a high-risk pregnancy\n* Pregnant women who voluntarily participate in prenatal education classes will be included.\n\nExclusion Criteria:\n\n* Foreign nationals with communication difficulties,\n* Multiple pregnancies,\n* Illiterate pregnant women,\n* Migrant pregnant women who do not speak Turkish,\n* Pregnant women with high-risk pregnancies,\n* Pregnant women not enrolled in prenatal education programs,\n* Pregnant women with intellectual disabilities,\n* Pregnant women who refuse to participate in the study will be excluded.","49 Years",{"count":220,"type":20},140,[60],"The aim of this study is to evaluate the effects of stress management and epigenetic awareness training provided in prenatal classes on maternal stress levels, cortisol levels, and epigenetic awareness.\n\nThe main questions it aims to answer are:\n\n1. Do stress management and epigenetic awareness training provided in prenatal classes affect pregnant women's cortisol levels?\n2. Does the training affect pregnant women's knowledge and awareness of epigenetic effects?",[25],"2026-08-11",{"date":226,"type":37},"2026-08-13",{"date":228,"type":37},"2026-05-15",{"date":230,"type":20},"2026-12-15",{"name":232,"class":74},"Kahramanmaras Sutcu Imam University",{"id":234,"slug":235,"hasResults":12,"nctId":236,"briefTitle":237,"officialTitle":156,"acronym":238,"eligibilityCriteria":239,"healthyVolunteers":12,"sex":53,"minAge":54,"maxAge":4,"enrollmentInfo":240,"targetDuration":4,"studyType":58,"phases":242,"briefSummary":243,"conditions":244,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":247,"lastUpdatePostDateStruct":248,"startDateStruct":250,"completionDateStruct":252,"leadSponsor":254,"locationsCount":127},"100600948","substance-use-in-pregnancy---optimizing-retention-in-treatment-100600948","NCT07104123","Substance Use in Pregnancy - Optimizing Retention in Treatment","SUPPORT-MOM","Inclusion Criteria:\n\nConfirmed viable intrauterine pregnancy at any gestational age, or within three years postpartum\n\nSUD as defined in the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders or clinician documentation\n\nExclusion Criteria:\n\nDecline follow-up care at study site\n\nRequire immediate hospitalization for unstable medical or psychiatric conditions making them clinically unsuitable to participate in a research study",{"count":241,"type":20},40,[60],"Substance use during pregnancy is a leading cause of maternal morbidity and mortality in the United States, with 55-80% of postpartum patients disengaging from substance use disorder (SUD) treatment within one year of delivery. Structural and social determinants of health, including housing instability, transportation barriers, and limited childcare access, further exacerbate disparities in treatment retention.\n\nThis pilot study, conducted in two specialized prenatal care clinics, evaluates the feasibility and acceptability of two integrated strategies to promote sustained engagement in recovery-oriented services during the perinatal and postpartum periods. Aim 1 implements a standardized social needs screening and referral protocol to connect patients with community-based supports. Aim 2 pilots a contingency management intervention to incentivize recovery-supportive behaviors.\n\nFindings will inform the design of a larger multi-site randomized controlled trial to evaluate the impact of these interventions on treatment retention, overdose prevention, and maternal-infant health outcomes.",[166,25,245,246],"Postpartum","Contingency Management","2026-08-06",{"date":249,"type":37},"2026-08-10",{"date":251,"type":37},"2026-02-02",{"date":253,"type":20},"2027-09",{"name":181,"class":74},{"id":256,"slug":257,"hasResults":12,"nctId":258,"briefTitle":259,"officialTitle":260,"acronym":4,"eligibilityCriteria":261,"healthyVolunteers":12,"sex":53,"minAge":54,"maxAge":4,"enrollmentInfo":262,"targetDuration":4,"studyType":58,"phases":264,"briefSummary":265,"conditions":266,"keywords":268,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":247,"lastUpdatePostDateStruct":270,"startDateStruct":271,"completionDateStruct":273,"leadSponsor":275,"locationsCount":127},"100446757","rct-of-at-home-tdcs-for-depression-in-pregnancy-100446757","NCT05097586","RCT of At-Home tDCS for Depression in Pregnancy","Randomized Controlled Trial of At-home Transcranial Direct Current Stimulation (tDCS) for Depression in Pregnancy","Inclusion criteria:\n\n1. Adult, ≥18 years of age\n2. Singleton pregnancy, 12 to end of 32 weeks single gestation at randomization\n3. In a major depressive episode (MDE) with at least moderate symptom severity (PHQ-9 ≥10 and confirmed using MINI International Neuropsychiatric Interview as MDE without psychotic features)\n4. Assessed by a psychiatrist at one of the study recruitment sites during pregnancy, and offered the option of antidepressant medication for treatment but declined to use\n5. No new treatments for depression (i.e. psychological or somatic) and no pharmacological treatment for depression in the 4 weeks prior to starting treatment\n\nExclusion criteria:\n\n1. Active alcohol or substance use disorder in previous 12 months as assessed by GAIN-SS\n2. Active suicidality as assessed by the Columbia Suicide Severity Rating Scale (C-SSRS)\n3. Bipolar disorder as assessed by MINI International Neuropsychiatric Interview\n4. Schizophrenia or other psychotic disorder as assessed by MINI International Neuropsychiatric Interview\n5. Major unstable or life-threatening medical illness (e.g. such as advanced cancer), pre-eclampsia\u002Feclampsia in current pregnancy or neurologic illness or seizure history\n6. Major congenital anomalies or major obstetrical complications in current pregnancy (determined by clinical PI\u002FCo-I assessment)\n7. Metal implants in cranium or any electrical implants\n8. Benzodiazepine (except intermittent low-dose lorazepam no more than 2mg equivalent per day) or anticonvulsant use as these interfere with anodal tDCS\n9. Visibly non-intact skin\u002Frash on scalp areas at stimulation electrode sites\n10. Unable to consent or complete study measures in English, or unable to complete depression in pregnancy workbook (the attention-control) in French or English",{"count":263,"type":20},156,[60],"This is a randomized, sham-controlled trial to determine whether treatment with transcranial direct current stimulation (tDCS) is superior to a sham condition at reducing the symptoms of depression in pregnant people with moderate to severe depression. The study aims to enrol 156 participants across all sites. Data collection occurs at baseline, immediately after treatment, every 4 weeks during pregnancy and 4-, 12-, 26- and 52-weeks postpartum",[267,25,198],"Major Depression",[25,199,269],"Transcranial direct current stimulation",{"date":249,"type":37},{"date":272,"type":37},"2021-11-08",{"date":274,"type":20},"2028-06-30",{"name":276,"class":74},"Women's College Hospital",{"id":278,"slug":279,"hasResults":12,"nctId":280,"briefTitle":281,"officialTitle":282,"acronym":4,"eligibilityCriteria":283,"healthyVolunteers":12,"sex":53,"minAge":54,"maxAge":284,"enrollmentInfo":285,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":287,"conditions":288,"keywords":292,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":304,"lastUpdatePostDateStruct":305,"startDateStruct":306,"completionDateStruct":308,"leadSponsor":309,"locationsCount":311},"100651084","clinical-validation-of-an-artificial-intelligence-system-for-de-termining-fetal-lie-and-position-in-3rd-trimester-100651084","NCT07754071","Clinical Validation of an Artificial Intelligence System for De-termining Fetal Lie and Position in 3rd Trimester","Clinical Validation of an Artificial Intelligence System for Determining Fetal Lie and Position in 3rd Trimester","Inclusion Criteria:\n\n* Pregnant women aged ≥18 years.\n* Singleton pregnancy.\n* Gestational age ≥28+0 weeks.\n* Fetus in longitudinal lie (cephalic or breech presentation) as determined by the routine clinical ultrasound examination.\n* Able to understand Danish or English.\n* Able and willing to provide written informed consent.\n\nExclusion Criteria:\n\n* Multiple pregnancy.\n* Fetus in transverse lie.\n* Inability to provide written informed consent.","70 Years",{"count":286,"type":20},150,"This prospective clinical validation study aims to evaluate the diagnostic performance of an artificial intelligence (AI)-based navigational support system for determining fetal lie and presentation during third-trimester ultrasound examinations. Following routine clinical assessment by an expert clinician, three blind ultrasound sweeps will be obtained from each participant. The AI system will generate predictions of fetal lie and presentation from each sweep, which will be compared with the expert clinician's assessment as the reference standard. The study will also explore clinician perceptions of the system's usability and potential clinical value.",[25,289,290,291],"Fetal Presentation","Breech Fetal Presentation","Cephalic Fetal Presentation",[293,294,295,296,297,298,299,300,301,302,303],"fetal lie","fetal presentation","obstetric ultrasound","artificial intelligence","AI-assisted ultrasound","Navigation system","blind ultrasound sweep","third trimester pregnancy","clinical validation","Diagnostic accuracy","fetal orientation","2026-08-04",{"date":249,"type":37},{"date":307,"type":37},"2025-09-11",{"date":69,"type":20},{"name":310,"class":74},"Copenhagen Academy for Medical Education and Simulation",3,{"id":313,"slug":314,"hasResults":12,"nctId":315,"briefTitle":316,"officialTitle":317,"acronym":4,"eligibilityCriteria":318,"healthyVolunteers":16,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":319,"targetDuration":4,"studyType":58,"phases":321,"briefSummary":322,"conditions":323,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":304,"lastUpdatePostDateStruct":332,"startDateStruct":334,"completionDateStruct":336,"leadSponsor":338,"locationsCount":4},"100650383","the-effect-of-scenario-based-simulation-training-for-nutritional-counseling-during-pregnancy-on-nursing-students-anxiety-levels-self-efficacy-perceptions-and-clinical-skill-performance-100650383","NCT07747051","The Effect of Scenario-Based Simulation Training for Nutritional Counseling During Pregnancy on Nursing Students' Anxiety Levels, Self-Efficacy Perceptions, and Clinical Skill Performance","The Effect of Scenario-Based Simulation Training for Nutritional Counseling During Pregnancy on Nursing Students' Anxiety Levels, Self-Efficacy Perceptions, and Clinical Skill Performance: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Undergraduate nursing students enrolled in the Department of Nursing.\n* Willingness to participate in the study and provision of written informed consent.\n* No previous participation in scenario-based simulation training on pregnancy nutrition counseling or a similar topic.\n\nExclusion Criteria:\n\n* Failure to attend the intervention or complete the study procedures.\n* Incomplete completion of the pretest or posttest questionnaires.\n* Withdrawal from the study at any stage",{"count":320,"type":20},52,[60],"The Effect of Scenario-Based Simulation Training for Nutritional Counseling During Pregnancy on Nursing Students' Anxiety Levels, Self-Efficacy Perceptions, and Clinical Skill Performance: A Randomized Controlled Trial\n\nResearch Hypotheses\n\nH1: Scenario-based simulation training significantly reduces anxiety levels among nursing students.\n\nH2: Scenario-based simulation training significantly increases nursing students' perceived self-efficacy.\n\nH3: Scenario-based simulation training significantly improves nursing students' clinical skill performance.\n\nH0₁: Scenario-based simulation training has no statistically significant effect on nursing students' anxiety levels.\n\nH0₂: Scenario-based simulation training has no statistically significant effect on nursing students' perceived self-efficacy.\n\nH0₃: Scenario-based simulation training has no statistically significant effect on nursing students' clinical skill performance.",[324,325,326,25,327,194,328,329,330,331],"Student Nursing","Simulation Training","Standardized Patient","Counseling","Anxiety","Nutrition During Pregnancy","Clinical Competence","Randomised Controlled Trial",{"date":333,"type":37},"2026-08-05",{"date":335,"type":20},"2026-07-09",{"date":337,"type":20},"2026-08-09",{"name":339,"class":74},"Ayşenur Karakuş",{"id":341,"slug":342,"hasResults":12,"nctId":343,"briefTitle":344,"officialTitle":345,"acronym":4,"eligibilityCriteria":346,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":347,"targetDuration":4,"studyType":58,"phases":349,"briefSummary":350,"conditions":351,"keywords":353,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":304,"lastUpdatePostDateStruct":358,"startDateStruct":359,"completionDateStruct":361,"leadSponsor":363,"locationsCount":4},"100637355","storytelling-for-provider-empathy--patient-trust-in-obstetric-care-100637355","NCT07588308","Storytelling for Provider Empathy & Patient Trust in Obstetric Care","Co-Developing a Nurse-Led, Community-Engaged Intervention to Improve Labor Pain Management and Build Trust in Obstetric Care","Inclusion Criteria\n\nProvider Participants:\n\n* Licensed clinician employed or credentialed at Duke Health Birthing Centers (nurse, anesthesia care provider, obstetrician, or nurse midwife).\n* In clinical practice for at least 6 months post-orientation.\n* Able to read and understand English.\n\nPatient Participants:\n\n* Self-identified non-Hispanic Black American women.\n* Age ≥18 years.\n* Able to read and converse in English.\n* Receiving obstetric care from a provider who is already enrolled in the study.\n\nExclusion Criteria\n\nProvider Participants:\n\n* Providers in training or with \\\u003C6 months independent clinical practice.\n* Providers unwilling or unable to give informed consent.\n\nPatient Participants:\n\n* Under 18 years of age.\n* Non-English speakers (due to study survey language limitations).\n* Unable or unwilling to provide informed consent.",{"count":348,"type":20},120,[60],"Aim 3 is a provider-focused pilot randomized controlled trial evaluating a digital storytelling intervention to increase obstetric care providers' empathy and to examine associations with postpartum patient trust. Providers randomized to the intervention view a video of Black women's labor pain and care experiences and complete a brief reflection; control providers receive general culturally sensitive care materials. Outcomes include change in provider empathy (primary) and patient trust among Black postpartum patients under those providers' care (secondary). Risks are minimal and mitigated via consent, voluntary participation, the option to skip questions, and secure data practices.",[25,352],"Labor Pain",[354,355,356,357],"Empathy","Cultural Competency","Provider-Patient Relations","Trust",{"date":247,"type":37},{"date":360,"type":20},"2026-08",{"date":362,"type":20},"2027-08-31",{"name":73,"class":74},{"id":365,"slug":366,"hasResults":12,"nctId":367,"briefTitle":368,"officialTitle":369,"acronym":4,"eligibilityCriteria":370,"healthyVolunteers":12,"sex":53,"minAge":54,"maxAge":4,"enrollmentInfo":371,"targetDuration":373,"studyType":21,"phases":4,"briefSummary":374,"conditions":375,"keywords":379,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":304,"lastUpdatePostDateStruct":384,"startDateStruct":386,"completionDateStruct":388,"leadSponsor":390,"locationsCount":45},"100625448","comparison-of-non-invasive-mean-arterial-blood-pressure-measurements-at-the-arm-and-ankle-during-elective-cesarean-delivery-100625448","NCT07422766","Comparison of Non-Invasive Mean Arterial Blood Pressure Measurements at the Arm and Ankle During Elective Cesarean Delivery.","Observational Study Comparing Non-Invasive Mean Arterial Blood Pressure Measurements at the Arm and Ankle During Elective Cesarean Delivery to Facilitate Skin-to-Skin Contact.","Inclusion Criteria:\n\n* Women scheduled for elective cesarean under neuraxial anesthesia at CHU Sainte-Justine.\n* American Society of Anesthesiologists Physical Status I-III\n* Singleton pregnancy\n* Gestation ≥ 35 weeks\n* BMI \\\u003C 40\n* Able to consent in French or English\n\nExclusion Criteria:\n\n* Cesarean planned under general anesthesia.\n* Multiple pregnancy\n* Prematurity \\\u003C 35 weeks gestation\n* Major fetal anomalies\n* Morbid obesity (BMI ≥ 40)\n* Active labor\n* Emergency cesarean\n* Prisoners\n* Peripheral vascular disease requiring medication or treatment\n* Hypertensive diseases requiring medication\n* Inability to place blood pressure cuff on ankle (amputation, dysmorphism, etc.)\n* Complications requiring significant hemodynamic support (transfusions, inotropes, multiple vasopressors, etc.",{"count":372,"type":20},110,"1 Day","This observational study aims to compare mean arterial pressure measurements obtained using an ankle blood pressure cuff with those obtained using a standard upper-arm cuff in pregnant individuals undergoing elective cesarean delivery under spinal anesthesia. The primary objective is to determine the level of agreement between the two measurement sites.The main question\\[s\\] it aims to answer \\[is\u002Fare\\]:\n\nDemonstrate that the mean arterial pressure is similar between arm and ankle with the blood pressure cuff\n\nEvery participant will be their own control. (Measurements will be taken at both sites on every participant)",[25,376,377,378],"Cesarean Delivery","Blood Pressure Measurement in Pregnancy","Skin to Skin Contact",[380,381,169,382,383],"blood pressure","Mean arterial pressure","cesarean","skin to skin",{"date":385,"type":37},"2026-08-07",{"date":387,"type":37},"2026-02-26",{"date":389,"type":20},"2026-12",{"name":391,"class":74},"St. Justine's Hospital",{"id":393,"slug":394,"hasResults":12,"nctId":395,"briefTitle":396,"officialTitle":397,"acronym":4,"eligibilityCriteria":398,"healthyVolunteers":12,"sex":53,"minAge":4,"maxAge":4,"enrollmentInfo":399,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":400,"conditions":401,"keywords":402,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":304,"lastUpdatePostDateStruct":406,"startDateStruct":407,"completionDateStruct":409,"leadSponsor":411,"locationsCount":414},"100608924","study-of-ceftriaxone-and-benzathine-penicillin-g-during-pregnancy-100608924","NCT07207876","Study of Ceftriaxone and Benzathine Penicillin G During Pregnancy","Phase IV Study of the Pharmacokinetics and Safety of Ceftriaxone and Benzathine Penicillin G During Pregnancy","Inclusion Criteria:\n\n* Is of legal age or circumstance to provide independent informed consent as determined by site standard operating procedures (SOPs) and consistent with Institutional Review Board (IRB) policies and procedures and is willing and able to provide written informed consent for her own and, if applicable (Arm 2), her infant's study participation\n* At screening, has a viable singleton intrauterine pregnancy of any gestational age confirmed by fetal ultrasound, as determined by the site investigator based on medical records, with trimester documented based on the best available obstetric estimate\n* At screening, is receiving or expected to receive one of the following drugs under study as prescribed by a clinical care provider and documented in medical records:\n\n  * Ceftriaxone: IV or IM administration for an indication other than syphilis\n  * Benzathine penicillin G: IM administration for treatment of syphilis\n* At entry, expects to remain in the geographic area of the study site during pregnancy and at least 30 days postpartum\n\nExclusion Criteria:\n\n* Previously enrolled in this study\n* Requires desensitization to ceftriaxone or benzathine penicillin G as determined by the site investigator based on pregnant participant report and available medical records\n* Has any of the following as determined by the site investigator based on pregnant participant report and available medical records:\n\n  * Current indication for hemodialysis\n  * Current indication for intensive care unit hospitalization\n  * Creatinine (Cr) ≥ 3.5 x upper limit of normal (ULN) at any time during the current pregnancy and\u002For chronic kidney disease Stage 5\n* Receipt of any of the following prohibited medications within seven days prior to entry as determined by the site investigator based on pregnant participant report and available medical records:\n\n  * Probenecid\n  * Penicillin\n* Arm 1A: any penicillin\n* Arm 1B: any penicillin\n* Arm 2: penicillin other than benzathine penicillin G\n\n  * Benzapril\n  * Chlorpropamide\n  * Diflunisal\n  * Irbesartan\n  * Ketoprofen\n  * Ketorolac tromethamine\n  * Meclofenamic acid\n  * Mefenamic acid\n  * Oxaprozin\n  * Parecoxib\n  * Penciclovir\n  * Pioglitazone\n  * Telmisartan\n  * Valsartan\n* Receipt of any investigational agent within seven days prior to entry as determined by the site investigator based on pregnant participant report and available medical records\n* Has any documented or suspected clinically significant condition that, in the opinion of the site investigator, would make participation in the study unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving study objectives",{"count":372,"type":20},"IMPAACT 2044 is a study to characterize the pharmacokinetics (PK) and safety of ceftriaxone and benzathine penicillin G during pregnancy. Up to 78 pregnant women receiving (1) ceftriaxone for indications other than syphilis or (2) benzathine penicillin G for treatment of syphilis from non-study clinical care providers will be enrolled at study sites located in the United States. Approximately 22 infants of pregnant participants receiving benzathine penicillin G will also be enrolled.",[25],[403,404,25,405],"Cefriaxone","Syphilis","Benzathine Penicillin G",{"date":247,"type":37},{"date":408,"type":37},"2026-02-16",{"date":410,"type":20},"2027-09-30",{"name":412,"class":413},"International Maternal Pediatric Adolescent AIDS Clinical Trials Group","NETWORK",9,{"id":416,"slug":417,"hasResults":12,"nctId":418,"briefTitle":419,"officialTitle":419,"acronym":420,"eligibilityCriteria":421,"healthyVolunteers":12,"sex":53,"minAge":54,"maxAge":134,"enrollmentInfo":422,"targetDuration":4,"studyType":58,"phases":424,"briefSummary":425,"conditions":426,"keywords":429,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":435,"lastUpdatePostDateStruct":436,"startDateStruct":438,"completionDateStruct":440,"leadSponsor":442,"locationsCount":45},"100615525","the-impact-of-virtual-doula-services-on-birth-outcomes-in-rural-communities-100615525","NCT07293741","The Impact of Virtual Doula Services on Birth Outcomes in Rural Communities","RIVER","Inclusion Criteria:\n\n* 18-45 years of age\n* pregnant (second or early third trimester) with their first child\n* reside in a rural zip codes in the U.S.\n\nExclusion Criteria:\n\n* non-singleton pregnancy\n* police custody or incarceration\n* infant to be separated from mother (e.g., placed for adoption, protective custody)\n* working with a doula prior to enrollment.",{"count":423,"type":20},614,[60],"This study will assess the impact of virtual doula care on birth and postnatal outcomes among rural mothers. The goal of virtual doula services is to improve access to care in underserved communities and decrease urban-rural differences in key maternal health outcomes including mode of birth (cesarean vs vaginal) and birth satisfaction. By implementing a digital randomized controlled trial, the study team will efficiently recruit a national sample of rural pregnant women to provide evidence of the effectiveness of virtual doula care, the appropriateness of virtual visits for different care and support needs, and the role of virtual care in improving maternal health.",[427,428,25,63],"Birth","Telehealth",[430,431,432,169,433,434],"telehealth","virtual","doula","birth","maternal health","2026-07-30",{"date":437,"type":37},"2026-08-03",{"date":439,"type":20},"2026-09",{"date":441,"type":20},"2029-12",{"name":443,"class":74},"RAND",{"id":445,"slug":446,"hasResults":12,"nctId":447,"briefTitle":448,"officialTitle":449,"acronym":4,"eligibilityCriteria":450,"healthyVolunteers":16,"sex":53,"minAge":54,"maxAge":451,"enrollmentInfo":452,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":454,"conditions":455,"keywords":457,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":465,"lastUpdatePostDateStruct":466,"startDateStruct":468,"completionDateStruct":469,"leadSponsor":471,"locationsCount":4},"100645814","maternal-periodontal-inflammation-and-pregnancy-outcomes-salivary-and-amniotic-biomarkers-100645814","NCT07699978","Maternal Periodontal Inflammation and Pregnancy Outcomes: Salivary and Amniotic Biomarkers","The Relationship Between Maternal Periodontal Inflammation and Pregnancy Outcomes: Evaluation Using Inflammatory and Oxidative Stress Biomarkers in Saliva and Amniotic Fluid","Inclusion Criteria:\n\n* Pregnant women between 28 and 32 weeks of gestation\n* Age 18 to 40 years\n* Singleton pregnancy\n* Systemically healthy\n* Normal gestational diabetes screening (oral glucose tolerance test within the hospital reference range)\n* Receiving only routine prenatal vitamin and iron supplementation (no therapeutic medications)\n* Low-risk pregnancy\n* No history of chorioamnionitis\n* No periodontal treatment within the previous 6 months\n* Able and willing to provide written informed consent\n\nExclusion Criteria:\n\n* Multiple pregnancy\n* Use of antibiotics or anti-inflammatory medications during pregnancy\n* Current smoking or alcohol consumption\n* Presence of an acute infection\n* Placental pathology\n* Major fetal anomaly\n* High-risk pregnancy as determined by the obstetrician\n* Refusal or inability to provide informed consent","40 Years",{"count":453,"type":20},80,"Periodontal disease is a chronic inflammatory condition that affects the tissues supporting the teeth and may contribute to systemic inflammation and oxidative stress. Increasing evidence suggests that maternal inflammation during pregnancy may be associated with adverse pregnancy outcomes, including preterm birth. However, the biological mechanisms linking maternal periodontal inflammation to the intrauterine environment remain unclear.\n\nThis prospective observational cohort study aims to investigate the relationship between maternal periodontal status and inflammatory and oxidative stress biomarkers measured in both saliva and amniotic fluid. Eighty healthy pregnant women between 28 and 32 weeks of gestation will be recruited from the Obstetrics and Gynecology Clinic of Gulhane Training and Research Hospital. Participants will undergo a comprehensive periodontal examination and provide unstimulated saliva samples. Amniotic fluid samples will be collected during delivery as part of routine obstetric care, without any additional invasive procedures.\n\nThe concentrations of 8-hydroxy-2'-deoxyguanosine (8-OHdG), malondialdehyde (MDA), interleukin-6 (IL-6), and matrix metalloproteinase-8 (MMP-8) will be measured in saliva and amniotic fluid using enzyme-linked immunosorbent assay (ELISA). Pregnancy outcomes, including gestational age at delivery, birth weight, and pregnancy complications, will also be recorded.\n\nThe study will evaluate whether maternal periodontal inflammation is associated with changes in inflammatory and oxidative stress biomarkers in saliva and amniotic fluid and whether these biomarkers are related to pregnancy outcomes. The findings may improve understanding of the biological relationship between oral health and pregnancy and may contribute to the identification of biomarkers associated with adverse pregnancy outcomes.",[92,25,456],"Preterm Birth",[458,25,456,459,460,461,462,463,464],"Periodontitis","Oxidative Stress","Inflammation","Saliva","Amniotic Fluid","8-Hydroxy-2'-deoxyguanosine (8-OHdG)","Interleukin-6 (IL-6)","2026-07-28",{"date":467,"type":37},"2026-07-29",{"date":34,"type":20},{"date":470,"type":20},"2027-08-15",{"name":472,"class":74},"Saglik Bilimleri Universitesi",{"id":474,"slug":475,"hasResults":12,"nctId":476,"briefTitle":477,"officialTitle":478,"acronym":4,"eligibilityCriteria":479,"healthyVolunteers":16,"sex":53,"minAge":54,"maxAge":480,"enrollmentInfo":481,"targetDuration":4,"studyType":58,"phases":483,"briefSummary":484,"conditions":485,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":465,"lastUpdatePostDateStruct":488,"startDateStruct":489,"completionDateStruct":491,"leadSponsor":493,"locationsCount":45},"100325253","maternal-smoking-cessation-and-pediatric-obesity-prevention-100325253","NCT03514602","Maternal Smoking Cessation and Pediatric Obesity Prevention","Pilot Study on Pediatric Obesity Prevention by Maternal Smoking Cessation in Pregnancy and Lactation","Inclusion Criteria:\n\n1. Able to read, understand, and speak English.\n2. Are 18-39 years old\n3. Are less than 20 weeks of gestation\n4. Have a singleton pregnancy\n5. Currently smoking one or more cigarettes per day, based on self-report.\n6. Currently smoking biochemically verified by a level of 1 or higher in urine cotinine test (i.e., \\>100ng\u002FmL cotinine concentration).\n7. Willing to try to quit or reduce smoking by behavioral intervention\n8. Willing to monitor smoking status by breath carbon monoxide and saliva cotinine.\n9. Willing to provide breath, saliva, and urine samples to test smoking status\n10. With low household income (meeting federal income eligibility guidelines for the Special Supplemental Nutrition Program for Women, Infants, and Children) and\u002For low education level (≤12 years). These disadvantaged pregnant women are very likely not to quit spontaneously, and thus need extra intervention most.\n11. Currently living in Erie County or Niagara County; don't plan to move out of these two counties during the current pregnancy.\n\nExclusion Criteria:\n\n1. Previous history of major chronic disease or blood clotting disorders such as cancer, thyroid disorders, heart disease, kidney disease\n2. Depression or have been diagnosed with depression or post-partum depression at any time\n3. In treatment for Axis 1 disorders that prevent them following smoking cessation interventions","39 Years",{"count":482,"type":20},48,[60],"The objective of this study is to test the effect of smoking cessation in pregnancy or in lactation on preventing rapid infant adiposity gain. Investigators propose a randomized, controlled experiment among smoking pregnant women from 1st prenatal care visit through 6 months of postpartum period. Two-phase randomization will be applied to separate the effects of smoking cessation in two different critical periods (i.e., pregnancy and lactation) on infant adiposity gain. Investigators will first randomly assign 40 smoking pregnant women into either the multicomponent intervention (N=30) or the education-only control group (N=10). The multicomponent intervention group will receive education and counseling, monitoring and feedback, contingent financial incentives, and family support, while the control group will receive education only. At the end of pregnancy, investigators will further randomize successful quitters (estimated N=20) from the multi-component intervention group into either the continuous multi-component intervention group in lactation (N=10) or the education-only control group (N=10). All women and their newborns will be followed from enrollment to 6 months postpartum. The key outcomes include maternal smoking abstinence confirmed by urine-cotinine and infant gain in weight-for-length z-score. Specific Aim 1 is to examine the effects of maternal smoking cessation intervention in pregnancy on infant gain in weight-for-length z-score from birth to 6 months. Specific Aim 2 is to examine the effect of maternal smoking abstinence intervention in lactation and infant post-weaning gain in weight-for-length z-score among the women who have successfully quit smoking in pregnancy.",[486,487,25],"Childhood Obesity","Smoking, Cigarette",{"date":435,"type":37},{"date":490,"type":37},"2015-07-01",{"date":492,"type":20},"2027-12-31",{"name":494,"class":74},"State University of New York at Buffalo",{"id":496,"slug":497,"hasResults":12,"nctId":498,"briefTitle":499,"officialTitle":500,"acronym":4,"eligibilityCriteria":501,"healthyVolunteers":12,"sex":53,"minAge":54,"maxAge":4,"enrollmentInfo":502,"targetDuration":4,"studyType":58,"phases":504,"briefSummary":506,"conditions":507,"keywords":509,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":513,"lastUpdatePostDateStruct":514,"startDateStruct":515,"completionDateStruct":517,"leadSponsor":519,"locationsCount":45},"100531388","early-phase-1-induction-of-labor-in-morbidly-obese-patients-100531388","NCT06199154","Induction of Labor in Morbidly Obese Patients","Induction of Labor in Morbidly Obese Patients: Comparison of 50 mcg and 25 mcg Misoprostol - A Randomized Control Trial","Inclusion Criteria:\n\n* Morbidly obese (BMI ≥ 40 kg\u002Fm2) at admission for induction of labor\n* Speaks English or Spanish\n* Gestational age between 34 weeks and 0 days and 42 weeks and 6 days\n* Age 18 years old or older\n* Viable, single, cephalic fetus\n* Intent to proceed with cervical ripening - cervical exam: dilation \\\u003C 5 cm\n* Contractions \\\u003C 5 per 10 minutes\n\nExclusion Criteria:\n\n* History of cesarean delivery\n* Contraindication to prostaglandin administration (significant myomectomy, prior cesarean delivery)\n* Contraindication to vaginal delivery (placenta previa, vasa previa, HIV with high viral load)\n* Contraindications to labor (cardiac, neurosurgical, need for cesarean)\n* Age \\\u003C 18yo\n* Fetal growth restriction with abnormal umbilical artery Doppler indices\n* Cervical dilation \\>5 cm\n* Contractions \\>5 per 10 minutes\n* Significant vaginal bleeding with concern for placental abruption\n* Non-reassuring fetal status or fetal heart rate decelerations\n* Fetal demise or major fetal anomaly\n* Inability to give consent",{"count":503,"type":20},162,[505],"EARLY_PHASE1","The goal of this randomized control trial is to compare different doses of Misoprostol (25 mcg vs 50 mcg) in induction of labor (IOL) in morbidly obese patients with BMI \\>40. It is known that morbid obesity is a risk factor for failed IOL and ultimately cesarean delivery (CD.) If the rates of vaginal delivery in this population can improve, then surgical morbidity can be reduced in these patients.",[508,25],"Morbid Obesity",[510,511,512],"induction of labor","morbid obesity","misoprostol","2026-07-27",{"date":467,"type":37},{"date":516,"type":37},"2024-07-15",{"date":518,"type":20},"2027-05",{"name":520,"class":74},"University of Maryland, Baltimore",{"id":522,"slug":523,"hasResults":12,"nctId":524,"briefTitle":525,"officialTitle":525,"acronym":4,"eligibilityCriteria":526,"healthyVolunteers":16,"sex":53,"minAge":54,"maxAge":4,"enrollmentInfo":527,"targetDuration":4,"studyType":58,"phases":529,"briefSummary":530,"conditions":531,"keywords":542,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":554,"lastUpdatePostDateStruct":555,"startDateStruct":557,"completionDateStruct":559,"leadSponsor":560,"locationsCount":311},"100635793","supporting-just-in-time-consent-for-prenatal-screening-the-inform-study-100635793","NCT07557303","Supporting Just-In-Time Consent for Prenatal Screening: The INFORM Study","Inclusion Criteria:\n\n* Currently pregnant and receiving care at a participating collaborative site - University of North Carolina, Chapel Hill; Zuckerberg Chan San Francisco General Hospital; University of Florida Health, Jacksonville.\n* 18 years of age and older\n* Able to read, speak, and understand English or Spanish\n* Has not previously been offered prenatal genetic screening for the current pregnancy\n* 24 weeks (6 months) gestational age or less\n\nExclusion Criteria:\n\n* Not pregnant, not a patient at a partner clinical site\n* Younger than 18 years of age\n* Not being able to read, speak, and understand English or Spanish\n* Has previously been offered prenatal genetic screening for the current pregnancy\n* Greater than 24 weeks gestational age (6 months)",{"count":528,"type":20},1400,[60],"This clinical trial is about prenatal genetic screening. It will test an intervention to help people make decisions about screening. The intervention is a short set of information cards about screening. This intervention is for pregnant participants. They will use the intervention on their mobile phone before they see their doctor.\n\nThe study has one main question:\n\n* Do participants who use the intervention feel more confident when they make a decision about screening?\n\nResearchers will compare participants who use the intervention to participants who do not. All participants will have their usual care when they visit their doctor.\n\nWhat will participants do?\n\n* Participants must be pregnant. They will sign up for the study before their first doctor's visit for their pregnancy. This is the visit where their doctor usually talks with them about screening.\n* Some participants will use the intervention before their first doctor's visit. Other participants will not use it.\n* All participants will talk with a researcher on the phone after their first doctor's visit.\n* Participants who use the intervention will answer a short survey on their phone.\n* A few participants who use the intervention will talk with a researcher a second time on the phone.",[532,533,534,25,535,536,537,194,538,539,540,541],"Delivery of Health Care","Genetic Testing","Humans","Noninvasive Prenatal Testing","Informed Consent","Internet-Based Intervention","Pregnant People","Decision Making","Health Education","Patient Education as Topic\u002FMethod",[543,544,545,546,547,548,549,550,551,552,553],"Non-invasive prenatal screening (NIPS)","Non-Invasive Prenatal Testing (NIPT)","Cell-free DNA (cfDNA)","Prenatal genetic screening","Informed consent","Decision making","Surveys and Questionnaires","Informed choice","Educational intervention","Decision Regret","Decision Satisfaction","2026-07-22",{"date":556,"type":37},"2026-07-23",{"date":558,"type":20},"2026-08-01",{"date":274,"type":20},{"name":561,"class":74},"Case Western Reserve University",{"id":563,"slug":564,"hasResults":12,"nctId":565,"briefTitle":566,"officialTitle":567,"acronym":568,"eligibilityCriteria":569,"healthyVolunteers":12,"sex":53,"minAge":54,"maxAge":4,"enrollmentInfo":570,"targetDuration":4,"studyType":58,"phases":572,"briefSummary":573,"conditions":574,"keywords":576,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":554,"lastUpdatePostDateStruct":580,"startDateStruct":582,"completionDateStruct":584,"leadSponsor":586,"locationsCount":588},"100609338","michigan-healthy-mom-mi-mom-pregnancy-improvement-web-application-trial-100609338","NCT07213284","Michigan Healthy Mom (MI-MOM) Pregnancy Improvement Web Application Trial","Site Randomized Trial to Evaluate Behavioral Intervention Via Web-Based Application (MI MOM- Michigan Healthy Moms Application) to Improve Pregnancy Outcomes","MI-MOM App","Inclusion Criteria:\n\n* Pregnant at 20 weeks gestation or less\n* 18 years of age or older\n* Access to smartphone with text messaging and internet access\n* Speaks English\n* Enrolled in Medicaid for health insurance\n\nExclusion Criteria:\n\n* Younger than 18 years old\n* Not pregnant or pregnant with more than 20 weeks gestation\n* No access to a smartphone with text messaging and internet access\n* Not English speaking\n* Not enrolled in Medicaid for health insurance",{"count":571,"type":20},500,[60],"The purpose of this research study is to see if using the MI MOM App improves pregnancy and postpartum health. There are two study groups, where one group is \"treatment as usual\" and the other is the \"MI MOM App\" group. Both groups will be asked to answer questions about their pregnancy health. Researchers will also retrieve vital records and Medicaid claims information related to pregnancy for both groups. Those in the \"MI MOM App\" group will receive mobile web app content and text messages with informational links and links to videos and micro-interventions. They will also identify up to three close friends or family members who will be invited to receive text messages. Those in the \"MI MOM App\" will also have the option to contact a community health worker as needed.",[25,575,90],"Pregnancy, Complications",[25,577,578,579,245],"App","Behavioral Intervention","Web-based Application",{"date":581,"type":37},"2026-07-24",{"date":583,"type":37},"2026-07-15",{"date":585,"type":20},"2031-12-31",{"name":587,"class":74},"Michigan State University",8,{"id":590,"slug":591,"hasResults":12,"nctId":592,"briefTitle":593,"officialTitle":593,"acronym":4,"eligibilityCriteria":594,"healthyVolunteers":16,"sex":53,"minAge":54,"maxAge":4,"enrollmentInfo":595,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":597,"conditions":598,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":604,"lastUpdatePostDateStruct":605,"startDateStruct":606,"completionDateStruct":608,"leadSponsor":610,"locationsCount":45},"100629105","placental-biology-in-health-and-disease-100629105","NCT07470320","Placental Biology in Health and Disease","Inclusion Criteria:\n\n* Female, aged 18 years or above\n* Willing and able to give informed consent for participation in the study\n* Able to read and understand written and spoken English to comprehend study materials and give informed consent\n* Non-pregnant women in good general health OR pregnant women who fall into one of the following:\n\n  * Healthy pregnancy\n  * Pre-eclampsia (PET) - defined by clinical diagnostic criteria, including hypertension and proteinuria\n  * Gestational diabetes mellitus (GDM) - diagnosed by standard glucose tolerance tests during pregnancy\n  * Fetal growth restriction (FGR) - diagnosed based on fetal weight or Doppler abnormalities\n  * Predisposed to PET - high-risk factors for PET such as maternal type 1 or type 2 diabetes, autoimmune diseases or multiple pregnancies\n\nExclusion Criteria:\n\n* Non-pregnant participants with active health conditions that could confound study outcomes\n* Pregnant participants with conditions unrelated to PET, GDM or FGR that could influence EV profiles e.g. active infections or malignancies",{"count":596,"type":20},360,"Pre-eclampsia (PET) is a condition characterised by high blood pressure and damage to other organs, and is a leading cause of maternal and fetal complications such as fetal growth restriction (FGR). Gestational diabetes mellitus (GDM) involves abnormal blood sugar levels during pregnancy and can have both short and long-term impacts on the health of the mother and child. Both conditions are linked to placental dysfunction but the precise mechanisms behind these links remain unclear.\n\nA major focus of this study is on extracellular vesicles (EVs) which are tiny, bubble-like particles released by the placenta into the mother's and baby's bloodstreams. These EVs act as messengers, carrying proteins, lipids and genetic material that can influence how cells function, even in parts of the body far from the placenta. Notably, the number and content of these EVs change in conditions like PET and GDM, suggesting they may play a role in the development of these complications.\n\nThis single-site, observational, laboratory study aims to investigate how these EVs contribute to maternal health and disease. To enable analysis across different physiological and pathological conditions pregnant participants with healthy pregnancies, pregnancies predisposed to PET and pregnancies complicated by GDM, FGR and PET will be recruited alongside healthy non-pregnant controls. Recruitment will be from the Oxford University Hospitals NHS Foundation Trust and the Nuffield Department of Women's and Reproductive Health, University of Oxford (who fund the research). Demographic and clinical data will be collected as well as blood, urine, breath, voice, placenta, umbilical cord, umbilical cord blood, amniotic fluid and\u002For uterine vein blood samples.\n\nThrough examining EV content and function, it is hoped a better understanding of their role in pregnancy complications will be gained, including their potential as non-invasive biomarkers for early detection and targeted treatments, improving outcomes for mothers and babies worldwide.",[599,600,601,602,603,25],"Pre-eclampsia","Gestational Diabetes Mellitus (GDM)","Fetal Growth Restriction (FGR)","Pregnancy Induced Hypertension (PIH)","Placenta","2026-07-21",{"date":556,"type":37},{"date":607,"type":37},"2025-12-16",{"date":609,"type":20},"2030-05-31",{"name":611,"class":74},"University of Oxford",{"id":613,"slug":614,"hasResults":12,"nctId":615,"briefTitle":616,"officialTitle":616,"acronym":4,"eligibilityCriteria":617,"healthyVolunteers":16,"sex":53,"minAge":54,"maxAge":134,"enrollmentInfo":618,"targetDuration":373,"studyType":21,"phases":4,"briefSummary":619,"conditions":620,"keywords":622,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":626,"lastUpdatePostDateStruct":627,"startDateStruct":628,"completionDateStruct":630,"leadSponsor":632,"locationsCount":45},"100621272","determinant-factors-in-excessive-gestational-weight-gain-physical-activity-nutritional-status-and-anxiety-100621272","NCT07368465","Determinant Factors in Excessive Gestational Weight Gain: Physical Activity, Nutritional Status, and Anxiety","Inclusion Criteria:\n\n* Being in the 3rd trimester of pregnancy\n* Being between 18 and 45 years old\n* Having the intellectual capacity to understand and respond to what is read.\n\nExclusion Criteria:\n\n* High-risk pregnancy\n* Multiple pregnancy\n* Having a chronic disease such as a systemic, neurological, orthopedic, etc.",{"count":286,"type":20},"This study aims to identify which of the following factors-physical activity level, nutritional status, or pregnancy-related anxiety-has the strongest influence on excessive gestational weight gain. Pregnant women in their third trimester who are being followed at Gebze Fatih State Hospital and meet the inclusion criteria will be referred to the Exercise Therapy Laboratory of the Department of Physiotherapy and Rehabilitation, Faculty of Health Sciences, Bezmialem Vakıf University. After being informed about the study and providing written informed consent, participants will undergo a face-to-face assessment. Data will be collected prospectively using a demographic information form, the Pregnancy Physical Activity Questionnaire (PPAQ), a nutritional status assessment form, and a pregnancy-related anxiety questionnaire.",[25,621],"Excessive Gestational Weight Gain",[623,624,625],"physical activity","nutritional status","anxiety","2026-07-20",{"date":604,"type":37},{"date":629,"type":37},"2026-01-02",{"date":631,"type":20},"2027-08-01",{"name":633,"class":74},"Bezmialem Vakif University",{"id":635,"slug":636,"hasResults":12,"nctId":637,"briefTitle":638,"officialTitle":638,"acronym":639,"eligibilityCriteria":640,"healthyVolunteers":12,"sex":53,"minAge":54,"maxAge":4,"enrollmentInfo":641,"targetDuration":4,"studyType":58,"phases":643,"briefSummary":644,"conditions":645,"keywords":647,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":651,"lastUpdatePostDateStruct":652,"startDateStruct":653,"completionDateStruct":654,"leadSponsor":656,"locationsCount":45},"100648004","ripening-approaches-for-prompt-induction-and-delivery---sequential-versus-concurrent-dilapan-s-and-misoprostol-to-achieve-vaginal-delivery-rapid-ds-100648004","NCT07717502","Ripening Approaches for Prompt Induction and Delivery - Sequential Versus Concurrent Dilapan-S and Misoprostol to Achieve Vaginal Delivery (RAPID-DS)","RAPID-DS","Inclusion Criteria:\n\n* Nulliparous patients with singleton pregnancies with vertex lie at term receiving prenatal care that are eligible for outpatient cervical ripening will be eligible\n\nExclusion Criteria:\n\n* age less than 18,\n* suspected major fetal anomalies (including suspected or proven chromosome anomalies, congenital cardiac disease expected to require neonatal intervention, and multiple anomalies suggestive of a complex syndrome),\n* fetal growth restriction\n* oligohydramnios\n* prior full thickness\n* uterine scar\n* placenta previa,\n* low-lying placenta,\n* premature rupture of amniotic membranes,\n* cervical dilation \\> 2 cm\n* modified Bishop score \\> 4\n* residence greater than 60 minutes from the hospital",{"count":642,"type":20},260,[60],"The purpose of this study is to compare the effectiveness of sequential versus combined multimodal cervical ripening strategies to achieve vaginal delivery within 24 hours among nulliparous patients with singleton, vertex pregnancies at term undergoing induction of labor.",[646,25],"Nulliparous Women Who Scheduled for Labor Induction",[648,649,650,512],"nulliparous","labor induction","cervical ripening","2026-07-16",{"date":604,"type":37},{"date":360,"type":20},{"date":655,"type":20},"2027-12",{"name":657,"class":74},"Ochsner Health System",{"id":659,"slug":660,"hasResults":12,"nctId":661,"briefTitle":662,"officialTitle":663,"acronym":4,"eligibilityCriteria":664,"healthyVolunteers":12,"sex":53,"minAge":54,"maxAge":4,"enrollmentInfo":665,"targetDuration":4,"studyType":58,"phases":667,"briefSummary":668,"conditions":669,"keywords":673,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":675,"lastUpdatePostDateStruct":676,"startDateStruct":677,"completionDateStruct":679,"leadSponsor":681,"locationsCount":588},"100610354","cash-transfers-to-pregnant-women-with-hiv-100610354","NCT07226492","Cash Transfers to Pregnant Women With HIV","A Pilot Trial of an Unconditional Cash Transfer for Pregnant Women With HIV in Botswana","Inclusion Criteria:\n\n* Age 18 years or greater\n* Botswana citizen\n* Seeking\u002Freceiving antenatal care at antenatal clinics managed by the District Health Management Teams in Gaborone and Mogoditsane-Thamaga District\n* Confirmed pregnancy by standard laboratory methods (generally urine testing)\n* HIV seropositive\n* Economically vulnerable (self-reported annual income below the Botswana poverty line of 14,000 BWP per year, equivalent to the international poverty line of $2.15 in 2017 purchasing power parity)\n\nExclusion Criteria:\n\n* Does not meet all of the inclusion criteria\n* Unable to provide consent\n* Cognitive impairment, per discretion of study staff\n* Cannot be in the same household as another enrolled study participant",{"count":666,"type":20},100,[60],"The goal of this study is to evaluate the effectiveness and implementation of an unconditional cash transfer intervention to improve mental bandwidth, ART adherence, and postpartum retention among pregnant women with HIV in Botswana.\n\nThe main questions it seeks to answer are:\n\n1. Do unconditional monthly cash transfers improve mental bandwidth relative to usual care among pregnant women with HIV?\n2. Do unconditional monthly cash transfers improve ART adherence (PDC) during pregnancy and the postpartum period?\n3. Is delivery of UCTs via mobile money feasible and acceptable in public ANC clinics in Botswana?\n4. What barriers and facilitators affect implementation, and how should the model be adapted for a larger trial or a policy pilot (e.g., a pregnancy support grant)?",[670,25,671,672],"HIV","HIV Antiretroviral Therapy (ART) Adherence","Post-partum",[674],"Cash-transfer","2026-07-14",{"date":583,"type":37},{"date":678,"type":37},"2026-03-09",{"date":680,"type":20},"2028-01-04",{"name":682,"class":74},"University of Pennsylvania"]